bpc-157 growth hormone receptor tendon fibroblasts study increased the cell number of BPC 157-treated BPC-157: What Research Shows (and
Description
Oncogene 38 (11), 19791988
BPC-157 is also not an FDA-approved treatment, and they've noted safety concerns surrounding this peptide, citing that it may contain impurities and may trigger an unwanted immune system response that could be dangerous
Inactivation can be further distinguished into -static substances which only inhibit further growth or -cidal substances which kill the organism (Mcdonnell and Russell, 1999)
GLOW is the simpler version focused on skin and tissue-quality remodeling
